peripheral nervous system disease: A disease involving the peripheral nervous system.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
262 |
4. Check minimum number of eventsNone |
262 |
5. Include endpointsNone |
262 |
6. Filter based on genotype QC (FinnGen only) |
237 |
Control definitions (FinnGen only)
- Control exclude
- G6_POLYNEU
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- G60-G64
- Name in latin
- Aliae morbositates systematis nervosi peripherici
Similar endpoints
↥List of similar endpoints to
Other disorders of peripheral nervous system
based on the number of shared cases.
Similar with more cases:
- Polyneuropathies and other disorders of the peripheral nervous system
- Neurological diseases
- Neurological diseases, wide definition
- Any prescribed medicine buy
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1252 | 584 | 661 |
| Only index persons | 1109 | 536 | 573 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.02 | 0.02 |
| Only index persons | 0.02 | 0.02 | 0.02 |
| Median age at first event (years) | |||
| Whole population | 59.48 | 59.38 | 59.73 |
| Only index persons | 57.53 | 58.02 | 57.07 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 237 | 128 | 109 |
| Unadjusted period prevalence (%) | 0.05 | 0.05 | 0.05 |
| Median age at first event (years) | 59.78 | 57.65 | 62.28 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 245
- Matched controls
- 2450
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
G64
ICD-10 Finland
Other disorders of peripheral nervous system
+∞
307.7
244
*
G62.9
ICD-10 Finland
Polyneuropathy, unspecified
90.1
51.6
56
8
N03AX12
ATC
[U] gabapentin; oral
5.7
37.1
96
249
N03AX16
ATC
[U] pregabalin
4.8
32.2
110
354
N06AX21
ATC
duloxetine; oral
4.8
22.9
63
166
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
5.4
22.0
50
112
G62.8
ICD-10 Finland
Other specified polyneuropathies
216.8
19.9
20
*
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
5.9
18.3
36
70
R20.2
ICD-10 Finland
Paraesthesia of skin
5.2
17.5
40
89
TAB00
NOMESCO Finland
Lumbar puncture
5.4
15.2
32
66
N02BF02
ATC
pregabalin; oral
5.1
15.0
34
75
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
5.2
13.2
29
62
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
2.7
13.1
117
618
NA3BG
NOMESCO Finland
Lumbar spine MRI examination with high intensity magnet
3.6
12.8
49
160
L28
ICPC
Limited function/disability (L)
3.0
12.8
72
298
N02BF01
ATC
gabapentin; oral
3.5
12.3
48
159
N03AE01
ATC
clonazepam; systemic
4.9
12.0
28
63
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.6
10.9
95
487
R52.2
ICD-10 Finland
Other chronic pain
5.4
10.7
22
44
M79.6
ICD-10 Finland
Pain in limb
2.4
10.5
135
822
N02AX02
ATC
tramadol; systemic, rectal
2.4
10.2
131
796
Z00.4
ICD-10 Finland
General psychiatric examination, not elsewhere classified
3.6
9.7
34
104
N06AX11
ATC
mirtazapine; oral
2.4
9.7
106
596
M79.2
ICD-10 Finland
Neuralgia and neuritis, unspecified
10.7
9.2
17
17
L12
ICPC
Hand/finger symptom/complaint
2.6
8.8
59
263
JN3BD
NOMESCO Finland
Extensive abdominal CT
3.2
8.5
37
130
AA1AD
NOMESCO Finland
CT of head and brain
2.3
8.4
92
511
G61.8
ICD-10 Finland
Other inflammatory polyneuropathies
+∞
8.4
8
*
R42
ICD-10 Finland
Dizziness and giddiness
2.4
8.1
73
372
S01
ICPC
Pain/tenderness of skin
4.5
8.1
20
47
A01
ICPC
Pain general/multiple sites
2.9
7.7
40
155
Z03.9
ICD-10 Finland
Observation for suspected disease or condition, unspecified
2.5
7.7
54
245
R07.4
ICD-10 Finland
Chest pain, unspecified
2.2
7.6
89
506
J45.9
ICD-10 Finland
Asthma, unspecified
2.4
7.5
62
304
H02AB06
ATC
prednisolone; systemic
2.1
7.5
135
904
G60.0
ICD-10 Finland
Hereditary motor and sensory neuropathy
+∞
7.3
7
*
N06AA09
ATC
amitriptyline; systemic
3.0
7.2
34
125
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
2.6
7.2
48
212
L17
ICPC
Foot/toe symptom/complaint
2.1
7.1
91
533
M54.5
ICD-10 Finland
Low back pain
2.1
7.0
103
634
Z01.8
ICD-10 Finland
Other specified special examinations
2.3
6.9
65
335
N99
ICPC
Neurological disease other
12.7
6.6
11
9
ACC51
NOMESCO Finland
Release of median nerve
3.3
6.6
26
86
R52.9
ICD-10 Finland
Pain, unspecified
2.7
6.6
37
150
A28
ICPC
Limited function/disability NOS
2.3
6.5
58
292
R4110
NOMESCO Finland
Physiotherapy
2.1
6.4
81
468
N03AX09
ATC
lamotrigine; oral
4.1
6.4
18
47
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.0
6.4
133
920
WX408
NOMESCO Finland
General anesthesy, balanced
2.1
6.3
75
424
G57.3
ICD-10 Finland
Lesion of lateral popliteal nerve
8.0
6.2
13
17
NH3AA
NOMESCO Finland
Foot and toes X-ray examination
2.9
6.2
30
112
C01DA14
ATC
isosorbide mononitrate; oral
2.4
6.1
48
229
A04
ICPC
Weakness/tiredness general
2.4
6.0
45
209
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
53
115
5.60
24.23
1.5
1.3
—
29.26
—
0
10
29
49
6.58
16.94
1.2
1.1
1.50
7.22
e6/l
1.00
18
36
29
51
6.32
16.28
1.2
1.2
4.68
132.85
e6/l
0.59
19
41
162
956
3.05
15.41
2.6
2.1
91.01
95.82
pmol/l
0.65
88
498
19
9
22.74
13.56
1.2
1.0
—
—
—
0
0
128
701
2.73
13.43
2.8
2.0
194.51
197.31
u/l
0.02
120
661
158
980
2.72
12.64
6.8
4.6
36.15
35.73
g/l
0.42
148
920
21
21
10.82
11.25
1.2
1.0
—
—
—
0
0
20
19
11.35
10.99
1.2
1.1
—
—
—
0
0
19
18
11.34
10.48
1.2
1.0
—
—
—
0
0
154
998
2.46
10.40
11.5
6.5
1.22
1.21
mmol/l
0.23
146
920
16
12
14.16
9.81
1.3
1.1
0.46
0.48
ratio
—
9
5
162
1099
2.40
9.51
8.6
7.5
1.22
1.21
mmol/l
0.59
143
952
176
1248
2.46
9.19
11.7
10.6
4.25
4.15
e9/l
0.24
158
1086
57
246
2.72
9.09
2.7
5.6
243.22
244.29
u/l
0.02
51
233
98
549
2.31
8.89
2.6
2.1
2.28
3.11
mg/l
4.23
86
478
145
955
2.27
8.88
2.7
2.4
80.66
77.76
nmol/l
0.57
133
854
74
372
2.42
8.55
4.1
3.2
0.80
0.82
mmol/l
0.70
67
350
61
283
2.54
8.36
1.9
1.8
—
—
—
0
0
30
95
3.46
8.12
1.2
2.4
39.25
40.27
u/l
0.10
24
86
109
657
2.19
8.11
2.1
1.7
20.20
21.07
nmol/l
0.25
96
551
123
780
2.16
8.01
4.4
3.4
2.35
2.36
mmol/l
0.19
114
704
89
502
2.21
7.75
1.3
1.3
3.83
1.71
u/ml
0.39
15
142
186
1405
2.34
7.59
6.0
4.7
—
350.91
—
0
22
22
59
4.00
7.54
1.3
1.3
—
—
—
0
0
57
268
2.47
7.53
1.9
1.9
—
—
—
0
0
23
65
3.80
7.34
5.9
4.2
23.23
1.68
ratio
0.59
13
37
140
969
2.04
6.86
4.0
3.0
141.50
130.51
ug/l
0.23
132
901
27
90
3.25
6.74
1.4
1.8
5.25
4.82
iu/ml
—
10
23
71
385
2.19
6.68
2.0
1.9
—
—
—
0
0
28
97
3.13
6.56
1.7
2.3
1.49
1.53
g/l
0.07
22
87
185
1444
2.15
6.22
4.3
3.3
57.10
47.46
u/l
0.53
177
1362
16
40
4.21
6.00
1.3
1.3
—
—
—
0
0
16
40
4.21
6.00
1.3
1.3
—
—
—
0
0
67
372
2.10
5.85
1.6
1.7
1061.05
1207.05
nmol/l
0.62
56
280
112
751
1.91
5.68
4.7
3.4
32.69
32.12
u/l
0.06
105
713
197
1600
2.18
5.61
6.6
4.4
13.78
12.00
mm/h
0.70
190
1485
83
509
1.95
5.46
3.9
4.2
1.02
1.02
kg/l
0.08
59
331
155
1177
1.86
5.12
4.5
4.0
0.00
0.02
estimate
0.50
28
215
20
66
3.21
5.07
1.4
1.4
7.69
1.79
u/ml
—
7
14
43
212
2.25
5.01
2.8
2.6
75.31
29.94
u/l
0.45
35
176
152
1153
1.84
4.98
4.4
3.9
0.00
0.00
estimate
-0.00
29
231
69
411
1.94
4.87
1.5
1.3
22.56
29.46
iu/ml
0.31
21
121
79
495
1.88
4.78
1.8
1.7
0.93
1.26
mg/l
0.90
59
398
64
375
1.96
4.73
4.4
2.9
0.79
0.82
e6/l
0.05
34
195
94
625
1.82
4.69
4.3
3.0
0.49
0.34
e6/l
0.45
77
446
73
452
1.88
4.56
1.7
1.9
409.86
439.33
pmol/l
0.51
64
377
59
344
1.94
4.40
4.2
3.1
3.31
2.42
e6/l
0.25
29
169
30
136
2.37
4.23
1.8
1.7
—
—
—
0
0
150
1167
1.74
4.18
4.4
4.0
0.00
0.00
estimate
-0.00
29
238
24
99
2.58
4.12
2.1
1.4
0.35
0.36
mg/l
0.04
15
43
60
369
1.83
3.76
1.4
1.3
1.21
9.79
u/ml
1.59
21
132
18
70
2.70
3.47
1.7
1.6
—
—
—
0
0
218
1946
2.09
3.33
6.3
5.5
1.65
1.95
mu/l
4.01
208
1793
190
1627
1.75
3.29
4.5
4.4
14.99
14.92
pmol/l
0.14
178
1482
67
443
1.71
3.24
7.3
3.7
362.48
299.86
ng/l
0.11
52
352
36
196
1.98
3.24
5.8
6.7
8.83
9.42
mmol/l
0.21
36
187
46
273
1.84
3.21
13.3
8.6
1.36
0.87
mmol/l
0.37
39
228
68
460
1.66
3.00
3.8
2.7
2.47
2.45
mmol/l
0.34
63
416
100
744
1.58
3.00
3.2
2.5
49.33
61.22
u/l
1.24
95
693
6
9
6.80
2.88
1.2
1.3
—
—
—
0
0
6
9
6.80
2.88
1.2
1.1
—
—
—
0
0
227
2085
2.21
2.76
27.0
16.1
22.65
23.23
mg/l
0.12
205
1724
23
113
2.14
2.72
1.3
1.3
—
—
—
0
0
114
889
1.53
2.70
3.7
3.9
0.00
0.00
estimate
-0.00
24
191
80
580
1.56
2.62
2.3
3.1
331.40
346.98
umol/l
0.79
72
504
113
885
1.51
2.60
5.3
4.0
30.77
37.28
ng/l
0.46
82
641
49
315
1.69
2.60
12.4
7.4
104.96
104.11
mmol/l
0.88
49
315
6
11
5.56
2.56
1.2
1.0
—
—
—
0
0
128
1032
1.50
2.55
3.4
2.8
—
—
estimate
—
0
0
76
551
1.55
2.48
2.9
2.4
—
—
—
0
0
94
723
1.49
2.30
3.8
3.3
710.09
1197.86
ng/l
2.21
88
607
15
66
2.36
2.29
1.7
1.4
281.50
314.55
ug/g
—
8
37
42
269
1.68
2.26
4.2
4.7
22.43
23.16
ug/l
0.01
34
222
147
1244
1.45
2.14
3.3
3.0
—
—
—
0
0
220
2032
1.81
2.12
5.7
5.3
6.11
5.98
mmol/l
0.56
211
1870
5
10
5.08
2.08
1.0
1.2
—
—
—
0
0
15
71
2.19
1.96
2.0
1.5
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
5
11
4.61
1.95
1.0
1.2
—
—
—
0
0
13
58
2.31
1.94
1.0
1.3
—
—
—
0
0
7
22
3.24
1.89
1.4
3.9
320.86
795.05
mg
—
7
22
5
12
4.23
1.83
1.2
1.1
—
—
—
0
0
36
237
1.61
1.75
2.3
3.6
5.98
5.71
kpa
0.87
36
231
23
135
1.78
1.69
2.0
2.5
0.64
0.62
%
0.10
23
135
10
43
2.38
1.61
1.7
5.9
—
152.17
—
0
6
18
100
1.86
1.58
2.6
2.0
—
—
—
0
0
93
757
1.37
1.55
4.7
4.1
11.81
8.01
mg/mmol
0.37
62
476
7
27
2.64
1.52
1.1
1.1
—
—
—
0
0
7
27
2.64
1.52
1.3
1.1
—
—
—
0
0
14
73
1.97
1.47
1.1
1.2
—
—
—
0
0
16
88
1.88
1.45
2.4
2.0
—
—
—
0
0
10
46
2.22
1.42
1.3
1.4
—
—
—
0
0
81
654
1.36
1.40
4.1
4.1
0.00
0.00
estimate
-0.00
28
217
5
17
2.98
1.36
1.0
1.2
—
—
—
0
0
22
139
1.64
1.28
2.1
2.5
1.53
1.19
%
0.68
22
139
13
70
1.91
1.26
1.2
1.3
—
—
—
0
0
14
78
1.84
1.24
3.6
2.8
—
—
—
0
0
12
64
1.92
1.20
1.1
1.6
—
—
—
0
0
6
26
2.34
1.19
3.7
3.0
—
—
—
0
0
215
2032
1.47
1.18
25.5
15.9
80.34
80.12
ml/min/173m2
0.05
194
1892
10
50
2.04
1.18
1.2
1.2
—
—
—
0
0
24
159
1.56
1.17
1.8
1.6
—
—
—
0
0
8
39
2.09
1.16
1.1
1.1
—
—
—
0
0
27
185
1.52
1.14
2.9
2.9
56.11
60.29
ml/min/173m2
—
9
83
7
32
2.22
1.09
1.9
1.4
—
—
—
0
0
221
2108
1.49
1.06
6.3
6.1
2.55
2.69
mmol/l
1.71
211
1956
78
650
1.29
1.06
2.9
3.4
0.04
0.01
estimate
0.31
26
185
7
34
2.09
1.03
1.0
1.1
—
28.88
—
0
8
20
132
1.56
1.00
1.5
1.3
246.40
161.34
u/ml
—
5
53
7
36
1.97
0.98
1.1
1.3
—
—
—
0
0
6
27
2.25
0.94
1.0
1.3
—
—
—
0
0
6
28
2.17
0.92
1.2
1.6
—
—
—
0
0
6
28
2.17
0.92
1.2
1.6
—
—
—
0
0
6
28
2.17
0.92
1.2
1.6
—
—
—
0
0
6
29
2.10
0.90
1.2
1.6
—
—
—
0
0
6
29
2.10
0.90
1.2
1.6
—
—
—
0
0
6
29
2.10
0.90
1.2
1.6
—
—
—
0
0
6
29
2.10
0.90
1.0
1.5
—
—
—
0
0
23
162
1.46
0.88
5.0
3.4
5.05
5.09
kpa
0.16
23
157
11
64
1.75
0.87
1.2
1.7
—
—
—
0
0
11
65
1.72
0.84
1.1
1.6
—
—
—
0
0
217
2080
1.38
0.83
5.3
5.4
4.39
4.61
mmol/l
2.77
207
1933
8
47
1.73
0.81
1.6
1.6
—
—
—
0
0
216
2074
1.35
0.77
5.2
5.3
1.42
1.46
mmol/l
0.66
203
1921
70
599
1.24
0.75
3.7
4.8
24.35
22.10
%
0.45
30
289
210
2011
1.31
0.74
7.5
6.7
39.89
39.70
mmol/mol
0.10
205
1891
184
1736
1.24
0.73
32.9
20.5
13.59
13.68
%
0.49
184
1723
5
25
2.02
0.73
1.6
1.2
—
—
—
0
0
22
161
1.40
0.71
2.5
3.8
72.54
82.44
ng/l
0.34
16
137
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
10
62
1.64
0.66
2.3
2.2
0.20
0.38
iu/ml
—
5
33
7
44
1.61
0.65
1.7
2.2
—
85.35
—
0
11
8
51
1.59
0.61
1.3
1.2
—
—
—
0
0
6
36
1.68
0.57
1.2
1.8
—
—
—
0
0
12
82
1.49
0.55
2.0
2.3
1.57
1.53
mg/l
0.06
12
69
9
65
1.40
0.51
1.6
1.8
237.33
335.34
mu/l
—
9
59
8
56
1.44
0.43
1.5
1.4
—
—
—
0
0
8
56
1.44
0.43
1.1
1.4
—
—
—
0
0
0
15
0.00
0.41
0.0
2.0
—
—
—
0
0
0
15
0.00
0.41
0.0
2.0
—
—
—
0
0
0
15
0.00
0.41
0.0
2.0
—
—
—
0
0
0
15
0.00
0.41
0.0
2.0
—
—
—
0
0
5
34
1.48
0.40
1.6
3.9
—
5127.40
—
0
5
8
61
1.32
0.40
1.5
1.4
—
—
—
0
0
15
115
1.32
0.40
1.0
1.0
—
—
—
0
0
0
19
0.00
0.39
0.0
1.4
—
42.65
—
0
19
204
1982
1.17
0.38
4.8
4.5
1.25
1.29
mmol/l
0.59
194
1823
6
41
1.47
0.36
1.5
1.5
—
—
—
0
0
6
41
1.47
0.36
1.7
2.0
7.83
7.69
pmol/l
—
6
41
99
929
1.11
0.31
1.8
2.0
1.47
1.38
mmol/l
0.60
89
764
7
52
1.36
0.31
1.0
1.1
—
3.37
—
0
7
7
53
1.33
0.31
1.3
1.4
—
—
—
0
0
50
452
1.13
0.30
2.9
3.1
0.67
0.77
ug/l
0.37
41
280
34
299
1.16
0.29
1.4
1.4
—
—
—
0
0
29
256
1.15
0.24
10.1
7.8
—
—
—
0
0
39
352
1.13
0.24
1.4
1.5
—
—
—
0
0
0
11
0.00
0.21
0.0
2.2
—
—
—
0
0
0
10
0.00
0.21
0.0
2.3
—
—
—
0
0
0
10
0.00
0.21
0.0
2.3
—
—
—
0
0
0
13
0.00
0.21
0.0
1.0
—
—
—
0
0
9
113
0.79
0.20
5.7
2.9
11.44
45.56
u/ml
—
9
108
6
50
1.20
0.20
1.5
1.6
—
—
—
0
0
80
760
1.08
0.19
5.6
5.4
2.25
2.62
ug/l
0.20
74
675
5
68
0.73
0.17
1.0
1.2
—
—
—
0
0
5
70
0.71
0.17
1.0
1.2
—
—
—
0
0
9
80
1.13
0.15
2.1
1.9
—
—
—
0
0
26
283
0.91
0.13
5.1
5.2
36.11
31.48
%
0.92
19
188
18
200
0.89
0.13
2.9
2.0
—
—
—
0
0
5
44
1.14
0.10
8.8
3.8
66.00
33.15
u/ml
—
5
44
5
45
1.11
0.10
1.2
1.2
0.73
0.96
nmol/l
—
5
38
7
64
1.10
0.08
1.3
1.7
260.29
236.88
pmol/l
—
7
58
9
85
1.06
0.07
2.1
2.1
—
—
—
0
0
9
101
0.89
0.06
1.0
1.4
—
—
—
0
0
23
219
1.06
0.04
3.6
3.4
—
—
—
0
0
18
184
0.98
0.00
2.6
1.8
—
—
—
0
0
20
195
1.03
0.00
2.1
1.5
—
—
—
0
0
6
59
1.02
0.00
1.0
1.4
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.9
—
42.51
—
0
9
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.9
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
10.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
1453.14
—
0
7
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
147.60
—
0
5
Mortality – FinRegistry
↥Association
Association between endpoint G6_PERIPHOTH and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| G6_PERIPHOTH | 1.811 [1.42, 2.32] | < 0.001 |
| Birth year | 0.991 [0.98, 1.0] | 0.162 |
During the follow-up period (1.1.1998 — 31.12.2019), 143 out of 508 females with G6_PERIPHOTH died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| G6_PERIPHOTH | 2.226 [1.7, 2.91] | < 0.001 |
| Birth year | 0.984 [0.97, 0.99] | 0.002 |
During the follow-up period (1.1.1998 — 31.12.2019), 185 out of 563 males with G6_PERIPHOTH died.
Mortality risk
Mortality risk for people of age
years, who have G6_PERIPHOTH.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.178% | 0.322% |
| 5 | 0.962% | 2.451% |
| 10 | 2.551% | 6.395% |
| 15 | 4.571% | 12.048% |
| 20 | 7.489% | 19.046% |
Relationships between endpoints
↥Index endpoint: G6_PERIPHOTH – Other disorders of peripheral nervous system
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data